News About: Pharm. Industry
Chong Kun Dang makes joint sales of diabetes and hyperlipidemia treatments with MSD KoreaOn the 4th, Chong Kun Dang(CEO Young-joo Kim) announced it made the joint sales agreement of 3 diabetes treatments and 2 hyperlipidemia treatments with MSD Korea.
Under the ter...
|
Dong-A ST cut price of Zydena by 67% at the maximumDong-A ST(Soo-hyung Kang) lowered the price of ‘Zydena’ by 67%, at the maximum, on the 1st of January this year.
According to the company, the price reduction was decided to st...
|
Foreigners own 5.13% of pharmaceutical stocks worth of KRW 4.2 trillion
Although the foreigner-owned stock portion reaches averagely 20% in the Korea stock market, it was observed the amount of foreigner-owned pharmaceutical stocks accounted barely for 5%.
That is, it means the domestic ...
Average price of pharmaceutical stocks increased 117% up in 2015
Stocks of listed pharmaceutical companies were observed to increase more than 100% on average in 2015 compared with the year before.
In particular, there were also stocks of 11 companies, whose prices were rapidly in...
A series of products introduced from multinational companies will create upheaval in the pharmaceutical industry
As pharmaceutical products introduced by domestic companies from multinational one have started to be expired in agreement, an upheaval in the industry is expected.
In order to overcome uncertainty which comes along ...
Rapid performance increase of RSA drugs requiring system modification
While the industry has had continuous issues about effectiveness of the Risk Sharing Agreement(RSA) System, drugs agreed to the system were observed to be increased in sales.
In an objective perspective about the agg...
35% of pharmaceutical R&D expenses are invested into personnel expenses
It was observed the ratio of R&D expenses to personnel expenses, when developing a new drug, is about 35% on average.
According to the aggregation result of the R&D/personnel expense ratio of 40 listed companies by t...
‘Temporary supply suspension’ due to shortage of GSK’s ‘DTaP’ and ‘DTaP-IPV’ vaccinesDomestic supply of GSK’s ‘Infanrix’ and ‘Infanrix-IPV,’ DTaP(diphtheria, tetanus, pertussis) and DTaP-IPV(diphtheria, tetanus, pertussis, polio) vaccines used initially for infa...
|
SK Chemicals announces the world’s first commercialization approval of tetravalent cell-cultured influenza vaccineOn the 24th, SK Chemicals(CEO Man-hoon Park) announced acquisition of commercialization approval of ‘SKYCellflu Quadrivalent,’ a tetravalent cell-cultured influence vaccine, fro...
|
Takeda left by CEO Choon-yup Lee appoints a new foreigner in the new yearThe CEO position of Takeda Pharmaceuticals Korea, which has been vacant since the resignation of CEO Choon-yup Lee, will be filled next year.
The headquarters of Takeda Pharmac...
|
